STI update: Testing, treatment, and emerging threats

Area of Science:

• Molecular diagnostics
• Infectious disease screening
• Urogenital infections

Background:

• Current diagnostic methods for sexually transmitted infections (STIs) can be invasive and time-consuming.
• Limited accessibility and patient discomfort hinder widespread screening for infections like gonorrhea and chlamydia.
• Mycoplasma genitalium represents a growing challenge in STI diagnostics.

Purpose of the Study:

• To evaluate the potential of rapid, sensitive molecular diagnostic tests for common STIs.
• To assess the feasibility of using patient-collected samples (urine, self-swabs) for STI testing.
• To determine if these methods improve patient acceptance and diagnostic timeliness.

Main Methods:

• Development and validation of molecular assays for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium.
• Utilizing urine and self-collected vaginal/urethral swabs as sample types.
• Assessing test sensitivity, specificity, and patient preference.

Main Results:

• The developed molecular tests demonstrated high sensitivity and specificity for all targeted pathogens.
• Urine and self-collected swabs proved to be effective and preferred sample types by patients.
• The rapid nature of these tests significantly reduces turnaround time for diagnosis.

Conclusions:

• Fast, sensitive molecular diagnostics using urine or self-collected swabs enhance STI screening accessibility and patient experience.
• These advancements facilitate earlier and more accurate diagnosis and treatment of gonorrhea, chlamydia, trichomoniasis, and Mycoplasma genitalium.
• Molecular testing with patient-convenient sample collection is crucial for improving public health outcomes related to STIs.